ISSAR Pharma

Home       About Us      Our History

We are proud to reach a turning point in the world of science like never before.

Ram Isanaka-FOUNDED ISSAR PHARMACEUTICALS-to develop new peptide molecules addressing the unmet healthcare needs.

ISSAR conducted the FIRST HUMAN CLINICAL TRIALS FOR MELGAIN (phase 1). ISSAR was the first and the only company to have conducted phase 1 clinical trial in India since independence.

ISSAR commercialised the first ever peptide solution for Vitiligo.

MELGAIN was launched into the market for the treatment of VITILIGO by Dr. Reddy’s in India.

ISSAR bagged the DCGI Approval for phase I and II clinical trials for XYLENTRA®- a peptide based topical drug for second degree burn wounds.

ISSAR pharmaceuticals established their state-of-the-art, FDA-compliant, 62000 sq ft., manufacturing facility at Genome Valley, Hyderabad, India.

Successfully completed Phase 1 clinical trial for cancers (solid tumors).

ISSAR successfully completed phase III clinical trials for BURN WOUNDS TREATMENT XYLENTRA.

ISSAR initiated new drug development for regulatory markets.

ISSAR got the DCGI approval for manufacturing NEW BULK SUBSTANCE XYLENTRA.

ISSAR obtained approval for manufacturing and marketing XYLENTRA.

Today

In the News

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs
Cadila acquires skin treatment lotion Melgain from ISSAR Pharma
ISSAR Pharma develops first-ever peptide molecule for skin care
Dr.-Reddys-issar
Dr Reddy’s Laboratories Ltd (DRL) to emerge as one of the top five dermatology companies in India with their recent launch of Melgain licensed by ISSAR PHARMACEUTICALS